Page last updated: 2024-09-05

orantinib and Disease Exacerbation

orantinib has been researched along with Disease Exacerbation in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, H; Li, H; Liu, C; Qian, B; Yao, Y; Zhang, J	1
Calderan, L; Daducci, A; Degrassi, A; Farace, P; Galiè, M; Marzola, P; Merigo, F; Nicolato, E; Pesenti, E; Sbarbati, A	1
Enooku, K; Goto, T; Kanai, F; Koike, K; Kondo, Y; Masuzaki, R; Omata, M; Shiina, S; Tateishi, R; Yoshida, H	1

Trials

1 trial(s) available for orantinib and Disease Exacerbation

Article	Year
Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times. Journal of gastroenterology, 2012, Volume: 47, Issue:1 Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Oxindoles; Propionates; Protein Kinase Inhibitors; Protein Precursors; Prothrombin; Pyrroles; Time Factors; Treatment Outcome; Tumor Burden	2012

Article

Year

Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times.

Journal of gastroenterology, 2012, Volume: 47, Issue:1

Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Oxindoles; Propionates; Protein Kinase Inhibitors; Protein Precursors; Prothrombin; Pyrroles; Time Factors; Treatment Outcome; Tumor Burden

2012

Other Studies

2 other study(ies) available for orantinib and Disease Exacerbation

Article	Year
SU6668 modulates prostate cancer progression by downregulating MTDH/AKT signaling pathway. International journal of oncology, 2017, Volume: 50, Issue:5 Topics: Angiogenesis Inhibitors; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; Membrane Proteins; Neoplasm Invasiveness; Oxindoles; Propionates; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor beta; RNA-Binding Proteins; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2	2017
Inhibition of tyrosine kinase receptors by SU6668 promotes abnormal stromal development at the periphery of carcinomas. British journal of cancer, 2009, May-19, Volume: 100, Issue:10 Topics: Animals; Carcinoma; Cell Proliferation; Colonic Neoplasms; Disease Progression; HT29 Cells; Humans; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Receptor Protein-Tyrosine Kinases; Stromal Cells; Up-Regulation; Xenograft Model Antitumor Assays	2009

Article

Year

SU6668 modulates prostate cancer progression by downregulating MTDH/AKT signaling pathway.

International journal of oncology, 2017, Volume: 50, Issue:5

Topics: Angiogenesis Inhibitors; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; Membrane Proteins; Neoplasm Invasiveness; Oxindoles; Propionates; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor beta; RNA-Binding Proteins; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2

2017

Inhibition of tyrosine kinase receptors by SU6668 promotes abnormal stromal development at the periphery of carcinomas.

British journal of cancer, 2009, May-19, Volume: 100, Issue:10

Topics: Animals; Carcinoma; Cell Proliferation; Colonic Neoplasms; Disease Progression; HT29 Cells; Humans; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Receptor Protein-Tyrosine Kinases; Stromal Cells; Up-Regulation; Xenograft Model Antitumor Assays

2009